Unsafe
Not Aligned
Patient Risk:
High
Summary
Multiple claims either lack label support (dosing/strength, specific off-label uses, detailed mechanism) or are not anchored to the provided label text (e.g., UTI, Lyme). Several safety/administration and adverse reaction details are also unsupported because the relevant label sections are not provided in the excerpt.
Category Scores
Accurate Statements
Doxycycline hyclate belongs to the tetracycline class of antibiotics.
1 INDICATIONS AND USAGE; 12.1 Mechanism of Action
Doxycycline hyclate works by inhibiting bacterial protein synthesis.
12.4 Microbiology
Doxycycline hyclate is effective against a broad spectrum of bacteria.
12.4 Microbiology
Doxycycline hyclate is prescribed for respiratory tract infections.
1 INDICATIONS AND USAGE (1.3)
Doxycycline hyclate is prescribed for certain sexually transmitted infections.
1 INDICATIONS AND USAGE (1.2)
Doxycycline hyclate is used to treat acne.
1 INDICATIONS AND USAGE (1.8) (adjunctive therapy in acute intestinal amebiasis and severe acne)
As a tetracycline antibiotic, doxycycline hyclate binds to the 30S ribosomal subunit of susceptible bacteria.
12.4 Microbiology
Doxycycline hyclate can be taken with or without food.
17 PATIENT COUNSELING INFORMATION (absorption not markedly influenced by simultaneous ingestion of food or milk)
Patients should avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and discontinue therapy if phototoxicity occurs.
17 PATIENT COUNSELING INFORMATION
Doxycycline hyclate can interact with antacids containing aluminum, calcium, magnesium, or iron, which can decrease its absorption.
17 PATIENT COUNSELING INFORMATION
Patients should inform a healthcare provider about all medications and supplements being taken before starting doxycycline hyclate.
17 PATIENT COUNSELING INFORMATION
Unsupported Statements
Doxycycline hyclate is prescribed for urinary tract infections.
Not listed in the provided 1 INDICATIONS AND USAGE text.
Doxycycline hyclate is used to treat Lyme disease.
Not explicitly supported by the provided 1 INDICATIONS AND USAGE or 12.4 Microbiology text.
Doxycycline hyclate is used to treat cholera.
Cholera-specific treatment is not listed under 1 INDICATIONS AND USAGE; 12.4 lists activity against Vibrio cholerae isolates but does not state cholera as an indication in the provided text.
Binding to the 30S ribosomal subunit prevents the transfer of aminoacyl-t-RNA to the messenger RNA-ribosome complex.
Not stated in the provided label excerpt.
This prevents blocking of elongation of the bacterial peptide chain.
Not stated in the provided label excerpt.
Doxycycline hyclate ultimately inhibits protein synthesis essential for bacterial growth and survival.
Protein synthesis inhibition is supported, but this specific wording/claim about essentiality is not explicitly stated in the provided text.
A common dosage for doxycycline hyclate is 100 mg to 200 mg per day, divided into two doses.
No dosing regimen information is present in the provided available label sections.
For certain conditions like acne, lower doses may be prescribed.
No dosing statements for acne (or lower-dose regimens) are included in the provided available label sections.
A 50 mg strength is a lower strength dosage of doxycycline hyclate.
Provided dosage forms/strengths list 75 mg, 100 mg, 150 mg, and 200 mg; 50 mg is not shown.
The 50 mg dosage may be used in specific treatment regimens or for maintenance therapy.
No 50 mg strength and no maintenance-therapy language is present in the provided sections.
Doxycycline is available in capsules, tablets, and oral suspensions.
Provided label sections only describe doxycycline hyclate delayed-release tablets; no capsules/tablets/oral suspensions are mentioned.
Doxycycline hyclate is one salt form of doxycycline.
Not described in the provided label excerpt.
Other common forms of doxycycline include doxycycline monohydrate.
Not mentioned in the provided label excerpt.
Different forms of doxycycline can affect absorption.
Label excerpt supports absorption reduction with foods (esp. calcium) and some interactions, but does not discuss differences among doxycycline formulations affecting absorption.
Different forms can be chosen based on specific patient needs or prescribing preferences.
Not supported by the provided label excerpt.
Doxycycline hyclate is a well-established medication.
No such statement is present in the provided label excerpt.
The original patents for doxycycline hyclate have long expired.
No patent-history language is present in the provided label excerpt.
Generic versions of doxycycline hyclate are widely available.
No generic-availability statement is present in the provided label excerpt.
Doxycycline hyclate is manufactured by numerous pharmaceutical companies worldwide.
No manufacturing/market distribution statements are present in the provided label excerpt.
Numerous manufacturers include generic drug manufacturers producing the medication in various strengths and formulations.
No manufacturer/market distribution statements are present in the provided label excerpt.
Common side effects associated with doxycycline hyclate include nausea, vomiting, diarrhea, and sensitivity to sunlight.
The provided label excerpt does not include Adverse Reactions content (6 ADVERSE REACTIONS is not provided).
More serious side effects though less common can include severe allergic reactions.
No adverse reaction details are provided in the available label excerpt.
More serious side effects though less common can include liver problems.
No adverse reaction details are provided in the available label excerpt.
More serious side effects though less common can include effects on tooth development in children younger than 8 years old.
The provided warnings excerpt does not include this specific pediatric tooth-development statement.
Doxycycline hyclate should be taken with a full glass of water to prevent esophageal irritation.
Counseling advises drinking fluids liberally to reduce esophageal irritation and ulceration, but the specific instruction 'full glass of water' is not in the provided excerpt.
Taking doxycycline hyclate with food may reduce the risk of stomach upset.
The label excerpt addresses absorption effects and states absorption of doxycycline is not markedly influenced by food or milk; it does not state reduced risk of 'stomach upset' with food.
Stopping doxycycline hyclate early can lead to the infection returning.
Label excerpt states skipping doses/not completing full course may decrease effectiveness and increase resistance; it does not explicitly state infection will 'return.'
Doxycycline hyclate can interact with dairy products, which can decrease its absorption.
The excerpt states absorption of tetracyclines is reduced when taken with foods (especially those containing calcium) but also states doxycycline absorption is not markedly influenced by simultaneous ingestion of food or milk; this does not support a general claim that dairy decreases doxycycline absorption.
Doxycycline hyclate can interact with anticoagulant medications.
The provided available label excerpt does not include anticoagulant interaction text.
Interaction with anticoagulant medications can potentially increase bleeding risk.
No anticoagulant/bleeding-risk language is present in the provided available label excerpt.
Contradictions
Important Omissions
Label-supported contraindications, boxed warnings, and full warnings/precautions content are not present in the provided excerpt, limiting validation of safety statements beyond phototoxicity and absorption counseling.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Unsupported dose/strength regimen claims and multiple unsupported or non-label indications (UTI, Lyme; cholera indication framing) could drive clinically inappropriate use. Several safety/adverse-effect statements are unsupported due to missing adverse reactions/warnings content in the provided excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many key claims are not supported by the provided label excerpt, especially indications (UTI, Lyme; cholera framing) and dosing/strength regimens (100–200 mg/day; 50 mg strength).
Suggested Improvement
Restrict claims to those supported by the provided label sections: indications listed in 1 INDICATIONS AND USAGE; mechanism/protein synthesis inhibition in 12.4; patient counseling statements in 17. Remove or qualify unsupported dosing/strength and off-label indication claims not present in the label excerpt.